A new preclinical study funded by the National Institutes of Health (NIH) has identified a link between testosterone levels and survival in men with glioblastoma, an aggressive brain tumor. The research suggests that men with higher levels of testosterone tend to live longer after diagnosis compared to those with lower levels of the hormone.
Glioblastoma is the most common and deadly form of brain cancer in adults, with a median survival of approximately 15 months. Standard treatment includes surgery, radiation, and chemotherapy, but recurrence is nearly universal. The study's findings open a potential new avenue for treatment by targeting androgen signaling pathways.
The study, published in a peer-reviewed journal, analyzed data from male patients and conducted experiments in animal models. It found that androgens, such as testosterone, slowed tumor progression. This has implications for companies developing therapies for glioblastoma, including CNS Pharmaceuticals Inc. (NASDAQ: CNSP), which is working on novel treatments for brain cancers.
According to the press release announcing the study, the research provides a "interesting angle of consideration" for firms like CNS Pharmaceuticals. The company's lead candidate, Berubicin, is a chemotherapy agent designed to cross the blood-brain barrier and is currently in clinical trials for glioblastoma.
The study's authors caution that more research is needed to understand the mechanisms behind the testosterone-glioblastoma link and to determine whether manipulating hormone levels could be a viable treatment strategy. They also note that the findings are preliminary and based on preclinical data.
This research adds to a growing body of evidence that sex hormones play a role in cancer progression. Previous studies have shown that androgens can influence the growth of certain tumors, including prostate and breast cancers. The new study extends this understanding to brain cancer.
For patients and their families, the findings offer a glimmer of hope that new treatment options may emerge. However, experts emphasize that patients should not alter their hormone levels without medical supervision, as testosterone therapy can have side effects and may not be appropriate for all individuals.
The NIH-funded study underscores the importance of continued research into the biology of glioblastoma and the role of hormones in cancer. As scientists unravel the complex interactions between the endocrine system and tumors, new therapeutic targets may be identified.
BioMedWire, a division of IBN, reported on the study. IBN is a dynamic brand portfolio that provides communication services to the biotech and life sciences sectors. The company offers wire solutions, editorial syndication, press release enhancement, and social media distribution.
